Clinical trials: Advanced Solid Tumors Patients
NSCLC Stage IV
HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC
This is a Phase 1, open-label, multicenter, dose escalation study of HY1272 (administered via IV) evaluating both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) in patients diagnosed with locally advanced or…
- Trial name
- NCT06218940
- Testing
- HY1272
- Volunteers
- 40 people
- Sponsor
- Newsoara Biopharma Co., Ltd.
Advanced Solid Tumor Malignancies
HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies
The study will consist of a dose-escalation and dose-expansion component to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D), and to evaluate the preliminary antitumor activity of HX044.
- Trial name
- NCT06649708
- Testing
- HX044
- Where
- 3 sites in Australia
- Volunteers
- 100 people
- Sponsor
- Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Unspecified Adult Solid Tumor, Protocol Specific
Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers
A phase I study is conducted to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), safety and pharmacokinetics (PK) profile of a single agent CKD-516 injection on twice-weekly schedule in patients with…
- Trial name
- NCT01560325
- Testing
- CKD-516 inj.
- Where
- South Korea
- Volunteers
- 21 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Breast Cancer, Head and Neck Cancer
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00937417
- Testing
- docetaxel, vandetanib, proteomic profiling
- Sponsor
- SWOG Cancer Research Network
Unspecified Adult Solid Tumor, Protocol Specific
17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor
This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin when given together with paclitaxel in treating patients with metastatic or unresectable solid tumor.
- Trial name
- NCT00087217
- Testing
- tanespimycin, paclitaxel, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Adult Solid Neoplasm
Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
This phase I trial is studying the side effects and best dose of belinostat when given together with isotretinoin in treating patients with metastatic or unresectable solid tumors.
- Trial name
- NCT00334789
- Testing
- Belinostat, Isotretinoin, Pharmacological Study
- Where
- 5 sites in United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Esophageal Cancer
Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells.
- Conditions
- Breast Cancer, Esophageal Cancer, Gastric Cancer, Lung Cancer
- Trial name
- NCT00003125
- Testing
- ALVAC-CEA vaccine, aldesleukin, sargramostim
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Georgetown University
Advanced Solid Tumors
TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors
TLD-1 is a novel liposomal formulation of doxorubicin (PEG surface) that compared favorably to conventional liposomal formulations of doxorubicin including Caelyx® in preclinical in vivo models.
- Trial name
- NCT03387917
- Testing
- TLD-1, Caelyx
- Where
- 5 sites in Switzerland
- Volunteers
- 12 people
- Sponsor
- Swiss Cancer Institute
Malignant Solid Tumor
ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan
Evaluation of the safety, tolerability and pharmacokinetics (PK) of a single dose and multiple doses of ONO-4538 in Japanese patients with advanced malignant solid tumors, and exploratory evaluation of the pharmacological effect…
- Trial name
- NCT00836888
- Testing
- ONO-4538
- Where
- Japan
- Volunteers
- 17 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Lung Cancer, Malignant Mesothelioma
Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells.
- Conditions
- Lung Cancer, Malignant Mesothelioma, Metastatic Cancer
- Trial name
- NCT00020124
- Testing
- doxorubicin hydrochloride
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Advanced Solid Tumors, Cancer
A Clinical Study of PA5 in Patients With Advanced Solid Tumors
The goal of this clinical trial is to learn if PA5 is safe and works to treat advanced solid tumors in adults. It will also learn about the tolerability and PK/PD profile of PA5.
- Trial name
- NCT07702162
- Testing
- PA5
- Where
- 2 sites in China
- Volunteers
- 49 people
- Sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.
Advance Solid Tumors, Advanced Malignant Solid Tumors
A Study of CS231295 in Patients With Advanced Solid Tumors
This is a Phase I, single-arm, open-label, dose-escalation, multicenter clinical study of CS231295 in patients with advanced solid malignant tumors.
- Trial name
- NCT07612488
- Testing
- a small molecular multi-target kinase inhibitor
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- ThalassaX Therapeutics United States Ltd
Advanced Solid Tumour
A Study to Test Different Doses of BI 3968621 When Given Alone or With Ezabenlimab in Patients With Advanced Cancer
This study is open to adults with advanced cancer that cannot be removed by surgery or have spread to other parts of the body. The purpose of this study is to find the highest and most suitable dose of BI 3968621 that people with…
- Trial name
- NCT07851103
- Testing
- BI 3968621, ezabenlimab
- Where
- 10 sites in United States, Belgium and 3 more
- Volunteers
- 90 people
- Sponsor
- Boehringer Ingelheim
Solid Tumor
LZM009 to Treat Patients With Advanced Solid Tumors
To assess the safety and tolerability of IV administered LZM009 in subjects with advanced solid tumors who have progressed or are non-responsive to available therapies.
- Trial name
- NCT03286296
- Testing
- LZM009,recombinant humanized anti-PD-1 monoclonal antibody for injection
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Solid Tumors, Ovarian Cancer
A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours
ALM201/0001 is a Phase I, open-label, dose-escalation study of the safety, tolerability and pharmacokinetics (PK) of ALM201. Part 1 will be a dose-escalation study.
- Trial name
- NCT03427073
- Testing
- ALM201
- Where
- 3 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Almac Discovery
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of TY-1091 in Patients With Advanced Solid Tumors
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of TY-1091 administered orally in…
- Conditions
- RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer, Neoplasms
- Trial name
- NCT05675605
- Testing
- TY-1091
- Where
- China
- Volunteers
- 248 people
- Sponsor
- TYK Medicines, Inc
Solid Tumors
Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies
This is an open-label, multicenter, ascending, multiple dose study of nesvacumab (REGN910/ SAR307746) in combination with aflibercept ("ziv-aflibercept" in the U.S.)
- Trial name
- NCT01688960
- Testing
- nesvacumab (REGN910/ SAR307746), aflibercept (ziv-aflibercept)
- Where
- 6 sites in United States, Canada
- Volunteers
- 48 people
- Sponsor
- Regeneron Pharmaceuticals
Solid Tumors, Adult, PIK3CA Mutation-Related Tumors
Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma
This phase I/II trial tests the safety, side effects, and best dose of alpelisib and whether alpelisib and carboplatin work to shrink tumors in patients with solid tumors or human papillomavirus (HPV) positive squamous cell…
- Conditions
- Solid Tumors, Adult, PIK3CA Mutation-Related Tumors, PIK3CA Mutation, Human Papillomavirus-Related Carcinoma
- Trial name
- NCT05472220
- Testing
- Alpelisib, Carboplatin, Hyperpolarized Carbon-13 (13C) Pyruvate
- Sponsor
- Pamela Munster
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study
This phase I trial studies the side effects and best dose of adavosertib when given together with olaparib in treating patients with solid tumors that have spread to other places in the body (advanced) with selected mutations.
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Trial name
- NCT04197713
- Testing
- Adavosertib, Olaparib
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Clear Cell Carcinoma, Endometrial Cancer
TR115 in ARID1A-Mutated Advanced Solid Tumors
This is an open-label, multicenter, exploratory Phase II study to evaluate the efficacy and safety of TR115, an EZH2 inhibitor, in patients with advanced solid tumors carrying ARID1A gene mutations.
- Conditions
- Ovarian Clear Cell Carcinoma, Endometrial Cancer, Stomach Cancer Recurrent, Urinary Bladder Cancer
- Trial name
- NCT07793318
- Testing
- TR115
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tarapeutics Science Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.